Responses to imatinib versus IFN plus cytarabine in newly diagnosed patients with CML in chronic phase
. | CHR, % . | MCR, % . | CCR, % . | Progression-free survival, 14 mo . |
|---|---|---|---|---|
| Imatinib, n = 553 | 95.3 | 85.2 | 73.8 | 92.1 |
| IFN + cytarabine, n = 553 | 55.5 | 22.1 | 8.5 | 73.5 |
| P | .001 | .001 | .001 | .001 |
. | CHR, % . | MCR, % . | CCR, % . | Progression-free survival, 14 mo . |
|---|---|---|---|---|
| Imatinib, n = 553 | 95.3 | 85.2 | 73.8 | 92.1 |
| IFN + cytarabine, n = 553 | 55.5 | 22.1 | 8.5 | 73.5 |
| P | .001 | .001 | .001 | .001 |
Median duration of follow-up equaled 19 months. CHR indicates complete hematologic response; MCR, major cytogenetic response; and CCR, complete cytogenetic response.